Search Results - "Margalef, N. Mulet"

Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer by Cedrés, S., Torrejon, D., Martínez, A., Martinez, P., Navarro, A., Zamora, E., Mulet-Margalef, N., Felip, E.

“…Background Neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, has been associated with worse survival for many types of cancer. The aim…”
Get full text

G8 screening tool for treatment decision-making in elderly colorectal cancer patients by Marín, J., Soler, G., Martínez-Villacampa, M., Vázquez, S., Vivas, C. Santos, Margalef, N. Mulet, Teule, A., Salazar, R.

Get full text

Rectal Metastases from Squamous Cell Carcinoma: A Case Report and Review of the Literature by Mulet-Margalef, N., Cedrés, S., Montero, M. A., Martinez, P., Martínez, A., Felip, Enriqueta

“…Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer. The most frequent sites of distant metastasis are the liver, adrenal glands, bones and brain…”
Get full text

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC) by Argiles, G., Margalef, N. Mulet, Valladares-Ayerbes, M., de Prado, J. Vieitez, Grávalos, C., Alfonso, P. García, Santos, C., Tobeña, M., Sastre, J., Benavides, M., Cano, T., Loupakis, F., Garrote, M. Rodriguez, Rivera, F., Goldberg, R., Falcone, A., Bennouna, J., Ciardiello, F., Tabernero, J., Aranda, E.

Get full text

KRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients by Domenech Viñolas, M, Santos, C, Pérez, J, Varela, M, Martinez Villacampa, M, Teule, A, Ruffinelli Rodriguez, J C, Mulet Margalef, N, Soler, G, Ortega, A, Bergamino, M S, SanJuan, X, Torras, J, Ramos, E, Salazar, R

Get full text

Detection of frailty in elderly colorectal càncer patients: Is G8 a good screening tool? by Soler, G., Ruffinelli Rodriguez, J.C., Legido, R., Martinez Villacampa, M., Perez, F.J., Pardo-Burdalo, B., Marín, J.A., Morilla Ruiz, I., Heras Lopez, L., Vazquez, S., Recalde, S., Plana Serrahima, M., Santos, C., Mulet Margalef, N., Teule, A., Salazar, R., Galan, M.C., Saldaña, J.

Get full text

P-160Impact of KRAS mutation on patterns of metastasis in a series of colorectal cancer patients by Domenech Vinolas, M, Santos, C, Perez Martin Francisco, J, Varela, M, Merche, M, Grasselli, J, Teule, A, Soler, G, Mulet Margalef, N, Bergamino Sirven, M, Ortega Franco, A, Sanjuan, X, Salazar, R

Get full text

PO-477 BCL-Xl inhibition enhances dinaciclib-induced cell death in soft-tissue sarcoma cell lines by Rello-Varona, S, Fuentes-Guirado, M, López-Alemany, R, Contreras-Pérez, A, Mulet-Margalef, N, Garcia-Monclús, S, Garcia del Muro, X, Tirado, OM

“…IntroductionMetastatic disease in soft-tissue sarcomas (STSs) lack successful treatments. Mortality rates are indeed quite high. Dinaciclib is a representative…”
Get full text

96PD RETROSPECTIVE REVIEW OF PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) by Pérez, S.M. Cedrés, Torrejón, D, Martínez, P, Núñez, I, Mulet-Margalef, N, Rodríguez-Freixinós, V, Montero, M.A, Felip, E

Get full text

P-248G8 screening tool for treatment decision-making in elderly colorectal cancer patients by Marín, J, Soler, G, Martínez-Villacampa, M, Vázquez, S, Vivas, C Santos, Margalef, N Mulet, Teule, A, Salazar, R

Get full text

499P Heterogeneity in the immune inflamed biomarkers of MSS and MSI colorectal cancer by Argota, I. Baraibar, Rubio-Pérez, C., Martinez, G. Argiles, Montañá, F.J. Ros, Salvà, F., Margalef, N. Mulet, Urteaga, J.L. Cuadra, Castaneda, D.H. Marmolejo, Gonzalez, N. Saoudi, Ciardiello, D., Tabernero, J., Seoane, J., Elez, E.

Get full text

426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care by Valdivia, A.A., Salva, F., Ros, J., Baraibar, I., Argiles Martinez, G., Saoudi Gonzalez, N., Garcia, A., Mulet Margalef, N., Cuadra Urteaga, J.L., Capdevila, J., Salud Salvia, M.A., Paez, D., Casado, E., Comas, R., Ruiz-Pace, F., Villacampa Javierre, G., Acosta Eyzaguirre, D.A., Dienstmann, R., Elez Fernandez, M.E., Tabernero, J.

Get full text

461P Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR) by Argota, I. Baraibar, Ros, J., Comas, R., Aguilar, S., Salva, F., Garcia, A., Cuadra Urteaga, J.L., Saoudi Gonzalez, N., Mulet Margalef, N., Hernando, J., Capdevila, J., Martí, M., Espín, E., Garralda, E., Nuciforo, P., Dienstmann, R., Vivancos, A., Tabernero, J., Elez Fernandez, M.E.

Get full text

35P Toxicity and safety of novel immuno-oncology (IO) treatments after prior immune checkpoint inhibitors (ICIs) exposure by Valdivia, A.A., Hernando, A., Saavedra, O., Berché, R., Braña, I., Garcia, I. Matos, Ázaro, A., Villar, M. Vieito, Alonso, G., Galvão, V., Oberoi, H.K. Oberoi, Wornham, N.A., Madrid, L. Fariñas, Margalef, N. Mulet, Barrera, R. Morales, Gomez, P. Iranzo, Couselo, E. Muñoz, Tabernero, J., Dienstmann, R., Garralda, E.

Get full text

487P Use of patient-derived tumour organoids to identify acquired treatment resistance and determine optimal post-progression combinations in metastatic colorectal cancer by Martini, G., Borreil, I. Puig, Ramirez, L., Chicote, I., Mancuso, F.M., Caratu, G., Serres-Créixams, X., Fasani, R., Jimenez, J., Montañá, F.J. Ros, Argota, I. Baraibar, Ciardiello, D., Margalef, N. Mulet, Dienstmann, R., Vivancos, A., Elez, E., Palmer, H., Tabernero, J., Martinez, G. Argiles

Get full text

477P Genomically-matched therapy in refractory CRC according to ESCAT by Margalef, N. Mulet, Castillo, C., Mosteiro, M., Martinez, J. Perez, PAdrol, I., Aguilar, S., Villacampa, M. Martinez, Rodriguez, J.C. Ruffinelli, Losa, F., Vega, A. Teulé, Soler, G., Castany, R., Capdevila, F., Gil-Martin, M., Cuadra, C., Elez, E., Garralda, E., Salazar, R., Dienstmann, R., Santos, C.

Get full text

512PKRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients by Domenech Viñolas, M, Santos, C, Pérez, J, Varela, M, Martinez Villacampa, M, Teule, A, Ruffinelli Rodriguez, J C, Mulet Margalef, N, Soler, G, Ortega, A, Bergamino, M S, SanJuan, X, Torras, J, Ramos, E, Salazar, R

Get full text

RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer by Martini, G., Elez, E., Mancuso, F.M., España, M A Gomez, Caratù, G., Matito, J., Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A., Comas, R., Vivas, C Santos, Perez-Lopez, R., Nuciforo, P.G., Casanovas, O., Dienstmann, R., Tabernero, J., Aguilar, E Aranda, Vivancos, A.

Get full text

575P - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer by Martini, G., Elez, E., Mancuso, F.M., España, M A Gomez, Caratù, G., Matito, J., Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A., Comas, R., Vivas, C Santos, Perez-Lopez, R., Nuciforo, P.G., Casanovas, O., Dienstmann, R., Tabernero, J., Aguilar, E Aranda, Vivancos, A.

“…So far, no biomarkers of response to anti-angiogenic drugs are available in colorectal cancer (CRC) treatment. Liquid biopsy technique identifies actionable…”
Get full text

575PRAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer by Martini, G, Elez, E, Mancuso, F M, España, M A Gomez, Caratù, G, Matito, J, Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A, Comas, R, Vivas, C Santos, Perez-Lopez, R, Nuciforo, P G, Casanovas, O, Dienstmann, R, Tabernero, J, Aguilar, E Aranda, Vivancos, A

“…Abstract Background So far, no biomarkers of response to anti-angiogenic drugs are available in colorectal cancer (CRC) treatment. Liquid biopsy technique…”
Get full text